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Abstract
Background: Psoriasis is a common, chronic relapsing inflammatory skin disease. Lately, there is increasing evidence 
that psoriasis is more than "skin deep". Epidemiological studies showed that severe psoriasis might have also important 
systemic manifestations such as metabolic deregulations, cardiovascular disease (CVD) and increased mortality. 
Moreover, recently psoriasis patients were found to have platelet hyperactivity.
Case Presentation: This is a case report and review of the literature. We present a patient with long standing severe 
psoriasis vulgaris with marked thrombocytosis. His thrombocytosis did not correlate with disease severity but rather 
with the different treatments that he was exposed to, subsiding only during treatment with anti Tumor Necrosis Factor 
(TNF)- agents. A literature review revealed that in rheumatoid arthritis, another systemic inflammatory disease; 
interleukin (IL)-6 might be implicated in causing thrombocytosis.
Conclusion: This unique case report illustrates that different systemic treatments for psoriasis might have implications 
beyond the care of skin lesions. This insight is especially important in psoriasis patients in view of their deranged 
hemostatic balance toward a prothrombotic state, which might increase the risk of thrombosis and CVD. Therefore, 
further studies analyzing the effect of different drugs on platelets physiology are warranted.
Background
Psoriasis is a chronic relapsing prevalent disease affecting
2-4% of the world's population [1-3]. Severe psoriasis is a
disabling disease affecting the physical and emotional
well-being of patients, and its effect on quality of life is
similar to that seen with other major medical diseases
such as diabetes, rheumatoid arthritis, and cancer [4,5].
Moreover, it is increasingly being recognized that in
patients with severe or long-lasting disease, psoriasis is
not merely a skin disease but is probably associated with
other co-morbidities. Recently, studies based on large
cohorts showed that severe psoriasis was association with
metabolic derangements [6] and increased mortality [7].
Cardio-vascular diseases (CVD) were found to be the
most common cause of death [8,9]. These data emphasize
that the increased risk for occlusive vascular events in
patients with severe psoriasis can be attributed not only
to metabolic dysregulation, traditional lifestyle risk fac-
tors such as obesity, smoking or alcohol which have been
also reported in these patients [10], but probably also to
an independent risk directly resulting from the duration
and severity of psoriatic inflammation.
We report a patient with long-standing severe psoriasis
vulgaris with persistent reactive thrombocytosis that
remitted only under anti TNF- therapy.
Recent data suggest that the hemostatic balance is
deranged toward a prothrombotic state in psoriasis
patients, which might be sustained by platelet hyperactiv-
ity, therefore this case pose a therapeutic dilemma con-
cerning the need to treat reactive thrombocytosis in
severe psoriasis patients.
Case Presentation
In November 2006, a 36 years old male presented with
severe plaque type psoriasis, to our hospital clinic. He has
had psoriasis for the last 13 years; first it was localized to
the scalp and periodically spread to other small areas of
his body so he could control his disease with topical ther-
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apy. However, for the last six years the disease spread and
covered the majority of his integument. He denied prior
history of psoriatic arthritis. He had a positive family his-
tory of psoriasis, which affected his father, sister and
paternal grandmother, but they all had a milder disease.
His past treatments included various topical agents and
several years ago he had a course of UVB with significant
improvement, however he could not resume photother-
apy because he lost his health insurance. Otherwise his
past medical history was unremarkable. He had no
known drug allergies and did not smoke. His current
medications included over the counter iron pills. He
denied any other systemic medications.
Examination revealed severely erythematous scaly,
excoriated thick plaques involving approximately 80% of
his body surface area, and pitting of his nails. The rest of
his physical examination was unremarkable. After com-
pletion of the screening tests which were within normal
limits except from mild normocytic anemia (HGB = 12.0
gr/d) and elevated platelets count (470 × 103/mc, normal
range 180-400 × 103/mc) and receiving informed consent
he was treated with efalizumab (Raptiva) 0.7 mg/kg SC
o n c e  w e e k l y  a n d  s u b s e q u e n t l y  1  m g / k g  a s  p e r  l a b e l .
Under treatment his skin condition has gradually
improved. However, after 3 months of treatment he had
started to complain of arthralgia first involving his right
ankle and latter on extending to 2 fingers in both hands
and eventually to his left ankle. Treatment with Iboupro-
fen 600 mg twice daily did not relieve his pain. X-ray anal-
ysis confirmed the diagnosis of psoriatic arthritis
therefore treatment with Efalizumab was interrupted
after 9 months. In addition during the 9 months of efali-
zumab therapy his platelets count rose substantially (Fig-
ure 1). Then, etanercept (Enbrel) 50 mg twice weekly was
started. After an initial flare of his skin condition, which
was expected after cessation of efalizumab, a significant
improvement of both his skin and joints ensued. Interest-
ingly during the sixteen months of etanercept treatment
his platelets count returned to normal. But unfortunately
due to health insurance coverage problems he had to stop
etanercept and consequently his skin conditioned dra-
matically deteriorated and resembled his baseline condi-
t i o n  w h e n  h e  f i r s t  r e p o r t e d  t o  o u r  c l i n i c .  T h e r e f o r e
cyclosporine (Neoral) 200 mg twice daily was introduced
for approximately 2 months till he received his insurance
approval for adalimumab (Humira) and again his skin and
arthritis gradually improved. His platelets count rose
while being off etanercept and even when he was treated
with cyclosporine and his skin condition started to
improve his platelets counts remained persistently high
and only after adalimumab was started they returned to
normal values.
Results and Discussion
Thrombocytosis is classified as either primary (familial
and clonal) or secondary. Unlike essential thrombocyto-
sis, which is usually a form of myeloproliferative disease,
reactive thrombocytosis is an exaggerated physiologic
response to a primary stimulus thus it may accompany
infections, iron deficiency anemia, hemorrhage, hypos-
plenism or chronic inflammatory diseases. Among other
inflammatory diseases thrombocytosis was reported as a
complication of inflammatory bowel diseases (IBD)
[11,12] and rheumatoid arthritis (RA). However, in psori-
asis, which is also a chronic inflammatory disease there is
only one previous report of reactive thrombocytosis.
That report included two patients with psoriasis who had
episodes of fever, arthritis, and general fatigue [13]. Their
symptoms seemed to be associated with increases in
serum levels of platelet counts, IL-6, and elevated serum
titers of C-reactive protein (CRP), which paralleled the
severity of clinical symptoms. Platelet count has also been
shown to correlate with disease activity in IBD. Similarly
thrombocytosis usually occurs during the active clinical
stages of RA and it was demonstrated to parallel disease
activity [14].
Our case is unique since he had mildly elevated platelet
counts at baseline, which continued to raise despite the
improvement of his skin condition a result of efaluzimab
treatment. This is specifically interesting since efali-
zumab, which is a humanized anti-CD11a monoclonal
antibody (IgG1) that acts by blocking the interaction of
lymphocyte function-associated antigen 1 with intracel-
lular adhesion molecule 1, was described to cause an
autoimmune thrombocytopenia in 0.3% of cases, based
on data of the tolerance of 3,291 efaluzimab treated
patients. There is only one other published case of a pso-
riasis patient that developed thrombocytosis while being
treated with efalizumab [15]. However in that case the
thrombocytosis diminished gradually, upon stopping the
efalizumab, and after 9 weeks, returned to normal values.
The onset mechanism of this phenomenon does not sug-
gest an explanation. However, it is known that the acti-
vated platelets express CD11a [16]. In our patient, the
thrombocytosis was probably not an adverse reaction to
efaluzimab as it continued even after the drug was inter-
rupted.
Efaluzimab is also known to infrequently cause new
onset or recurrent severe arthritis events, including pso-
riatic arthritis. And indeed while on efaluzimab treat-
ment our patient experienced severe arthritis, which was
later on diagnosed to be psoriatic arthritis, and therefore
this treatment was interrupted. The only case report of
reactive thrombocytosis in psoriasis was in two patients
who had also arthritis [13]. Therefore it is also possible
that the development of psoriatic arthritis could have
contributed to his rising platelet counts.
In our patient, the platelet count continued to rise while
cyclosporine was administered with gradual improve-
ment of his skin condition although, cyclosporine is
reported to cause thrombocytopenia in 2% or less of theDavidovici et al. BMC Dermatology 2010, 10:2
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treated patients and there is no other case report of
thrombocytosis during cyclosporine treatment.
I n  o u r  p a t i e n t  p l a t e l e t  c o u n t s  r e t u r n  t o  n o r m a l  o n l y
during the periods that he was treated with anti TNFs
(etanercept, adalimumab) and did not correlate with dis-
ease activity (Figure 1). The normalization of thrombocy-
tosis was previously reported following treatment of RA
patients with anti TNFs [17]. Attempts have been made
to explain increments in the platelet counts. Some
authors postulated that the symptoms and abnormal lab-
oratory findings in these patients might be related to
increased serum levels of IL-6, since IL-6 is a multi-
potential cytokine with B-cell activating, T-cell activat-
ing, and thrombocytopoietic functions [13]. It was previ-
ously demonstrated that thrombocytosis secondary to
the inflammation of RA can be modulated by proinflam-
matory megakaryocyte-related interleukins, IL-6, IL-1b
and IL-4 [18,19]. In patients with active inflammatory
bowel disease, Heits et al. [20], disclosed that the levels of
thrombopoietin (TPO), which is the main regulator hor-
mone of platelet production, were significantly increased
in association with thrombocytosis and elevated IL-6 lev-
els. Furthermore, it was demonstrated that IL-6-induced
thrombocytosis in mice is accompanied by enhanced
hepatic TPO mRNA expression and elevated TPO
plasma levels [20]. In addition administration of IL-6 to
cancer patients resulted in a corresponding increase in
TPO levels [20]. Similarly others have also identified pos-
itive correlations between platelet count and IL-6 and
between TPO and IL-6 [21]. Yet in their study they con-
firmed that TPO acts as an acute phase protein but
excluded the possibility that it is uniquely responsible for
thrombocytosis of inflammatory disorders. This might
recognize in IL-6 a credible candidate as a cooperating
factor.
Interestingly, in a relatively big study of 219 patients
with psoriasis and psoriatic arthritis, IL-6 was signifi-
cantly higher in patients with psoriasis and inflammatory
joint disease compared with patients having psoriasis of
the skin [22].
It should be remembered that Il-6 has also a central role
in the pathogenesis of psoriasis as T memory/effector
cells (Tmem/eff) isolated from psoriatic patients are
chronically activated and poorly suppressed by regulatory
T cells (Treg). IL-6, which signals through Stat3, allows
escape of T mem/eff cells from T reg-mediated suppres-
sion in a murine system. In a recent study, Goodman et al
[23], showed that IL-6 is elevated and most highly
expressed by CD31(+) endothelial cells and CD11c(+)
dermal dendritic cells (DCs) in lesional psoriatic skin.
They found that IL-6, but not other Stat3-activating
cytokines, was necessary and sufficient to reverse human
T cell suppression by Treg in an in vitro model using acti-
vated DCs as a source of IL-6. They identified cells within
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lesional tissue that co-express CD3, IL-17, and IL-6, indi-
cating that Th17 cells are present in vivo within the psori-
atic Tmem/eff population and contribute to IL-6-
mediated resistance to Treg suppression.
Cyclosporine is a calcineurin inhibitor that was
reported to increase IL-6 production and IL-6 mRNA
expression [24]. In fact this is suspected to be the mecha-
nism by which cyclosporine induces renal damage and
that the use of an IL-6-neutralizing antibody may be use-
ful in reducing cyclosporine-induced renal damage [25].
Moreover cyclosporine-upregulated IL-6 gene expression
in vivo, may explain in part the molecular mechanisms
responsible for cyclosporine -induced gingival over-
growth [26]. In a previous study cyclosporine induced IL-
1β expression in circulatory leukocytes and this might be
sufficient to induce IL-6 production in some tissues [27].
This is also probably the reason of the sustained and even
increase in platelet counts seen in our patient during
cyclosporine treatment.
Anti TNF- however down-regulates the production of
IL-1, IL-6, IL-8, and GM-CSF [28,29]. The reductions in
circulating IL-6 in anti TNF-treated RA patients were
reaching significance from the first day of treatment [30].
Therefore anti TNFs might normalize platelet counts
through the reduction of circulating IL-6 levels.
Furthermore, increased platelet activation and aggrega-
tion have been demonstrated to be the features of IBD
and has been proposed to contribute to the pathogenesis
of mucosal inflammation seen in the condition [31]. In
psoriasis patients, evidence for an in vivo platelet activa-
tion, which could contribute to the development of
thrombotic events, has also been established [32]. Spon-
taneous platelet hyperaggregability, mean platelet vol-
ume, plasma levels of β-thromboglobulin and platelet
factor 4, which are markers of platelet activation, were
found to be significantly higher in psoriasis patients com-
pared with that in controls. Interestingly, these markers,
as well as platelet aggregability were significantly reduced
after psoriasis had cleared [33]. Moreover, platelet regen-
eration time, measured as malondialdehyde (MDA)
recovery after aspirin ingestion, was significantly shorter
in psoriasis patients [34,35]. Finally, P-selectin expression
by platelets was also increased in psoriasis patients,
showing a direct correlation with disease severity [36].
Simultaneously, activated platelets may play a role in pso-
riasis pa thogenesis by fa voring leukocyte rolling in the
skin microvasculature [36] and platelet derived 12-
hydroxyeicosatetraenoic acid may increase keratinocyte
DNA synthesis [37].
Finally, there is a therapeutic dilemma because reactive
thrombocytosis (even at this level) is often not treated, as
t h e  c h a n c e  o f  t h r o m b o s i s  i s  v e r y  r a r e .  H o w e v e r ,  i t  i s
important to bear in mind that severe psoriasis itself is a
risk factor for metabolic derangements [6], cardiovascu-
lar diseases and thrombosis [7-9] probably as a result of
the chronic inflammatory nature of the condition. Thus,
some hematologists tend to give an anti-platelet agent or
low molecular weight heparin in these circumstances
e s p e c i a l l y  i f  t h e r e  i s  a n o t h e r  c o e x i s t i n g  r i s k  f a c t o r  f o r
thrombosis [38]. Until more is known about the patho-
physiology of the increased risk for CVD in psoriasis
patients, such a therapeutic approach might be recom-
mended.
Conclusion
Different anti psoriasis therapies might have different
effects on platelet physiology. In view of the increased
risk of thrombosis and CVD in severe psoriasis patients
further studies analyzing the effect of different drugs on
platelets physiology are warranted.
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